Robbins Geller Rudman & Dowd LLP Announces that ADMA Biologics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of ADMA Biologics, Inc. (NASDAQ: ADMA) publicly traded securities between August 9, 2024 and March 25, 2026, inclusive (the “Class Period”), have until August 10, 2026 to seek appointment as lead plaintiff of the ADMA Biologics class action lawsuit. Captioned Mazzarino v. ADMA Biologics, Inc., No. 26-cv-06918 (D.N.J.), the ADMA Biologics class action lawsuit charges ADMA Biologics and certain of ADMA Biologics’ top executive officers with violations of the Securities Exchange Act of 1934.

If you suffered substantial losses and wish to serve as lead plaintiff of the ADMA Biologics class action lawsuit, please provide your information here:

https://www.rgrdlaw.com/cases-adma-biologics-inc-class-action-lawsuit- ...

You can also contact attorneys Ken Dolitsky or Michael Albert of Robbins Geller by calling 800/851-7783 or via e-mail at [e-mail].

CASE ALLEGATIONS: ADMA Biologics is a biopharmaceutical company that develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases.

The ADMA Biologics class action lawsuit alleges that defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (i) ADMA Biologics engaged in an undisclosed related party transaction; (ii) ADMA Biologics used channel stuffing to create an appearance of revenue; and (iii) ADMA Biologics lacked adequate internal controls.

On March 24, 2026, Culper Research issued a report entitled “ADMA Biologics Inc (ADMA): Channel Stuffing, an Undisclosed Related Party Distributor, and -3% Real Growth in 2025 vs. +20% Reported.” Culper Research allegedly asserted that ADMA Biologics’ “reported growth is a fiction driven more than entirely be a de facto channel stuffing scheme and an undisclosed related party distributor,” adding that had ADMA Biologics “held payment terms steady rather than extending terms to inflate reported revenues, [ADMA Biologics] would have reported year-over-year revenue declines of 3% in 2025.” On this news, the price of ADMA Biologics stock declined over 16%, according to the complaint.

Schreibe Deinen Kommentar